Pilot Study to Evaluate the Effect of Zoledronic Acid (Zometa) on Occult Malignant Bone Marrow Cells in Patients With High Risk Early Stage Breast Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jun 2017 Status changed from active, no longer recruiting to completed as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
02 Jun 2017 Long term follow up results of adjuvent Zoledronic acid in high risk early stage breast cancer patients presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
14 Sep 2012 Planned number of patients changed from 35 to 45 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com